Drug Scandal Shocks France - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Scandal Shocks France
Scandals regarding diabetes treatment Mediator frequently dominate French press headlines. Mediator was only withdrawn from the French market in November 2009, despite reports dating back as far as the 1990s linking similar products to valvular heart disease and pulmonary arterial hypertension. The end result is a great dissatisfaction among the French public with the French medicines regulator and the pharmaceutical industry, prompting a thorough reform of the country's pharmacovigilance system.


Pharmaceutical Technology Europe
Volume 23, Issue 3

In France, public confidence in health authorities and pharmaceutical industry has been shaken by a safety scandal over the drug Mediator (benfluorex hydrochloride), which was marketed by Servier and acts as a hypolipidemic and hypoglycemic drug. Medicines containing this agent were first approved in Europe in the mid to late 1970s. Besides appearing on the French market as Mediator, the product was also available in Portugal, Spain and Italy, and benfluorex-containing products were also authorised, but not marketed, in Cyprus and Luxembourg.



Although Mediator was licensed in France for the treatment of diabetes, it became widely used offlabel in the country as a weight loss treatment. In November 2009, several reports appeared that linked the drug to valvular heart disease and pulmonary arterial hypertension.1 Upon review of this information, the French medicines regulator AFSSAPS (Agence franšaise de sÚcuritÚ sanitaire des produits de santÚ) suspended the product's marketauthorisation.

Following Mediator's market withdrawal, an initial study suggested that it was linked to 500 deaths in France between 1976 and November 2009;2 however, further research has suggested that the figure could be much higher, leading to an outcry from the French public and media. Much of the criticism has been directed at AFSSAPS, which is accused of failing to act earlier on available information and to draw conclusions from issues with structurally similar drugs.

Setbacks for anti-obesity drugs

Although there is continuing controversy regarding Mediator itself, the situation has wider implications for the field of anti-obesity drug development as a whole, which has already experienced setbacks such as the withdrawal of rimonabant. Companies developing products in this area will probably face higher regulatory hurdles and a skeptical public.

Obesity has long been recognised as a major cause of morbidity and mortality. This led to the idea that pharmacotherapy tackling obesity could be beneficial as an adjunctive support to diet, exercise and lifestyle modification. However, early agents in the field ran into safety problems, some of which were chemically related to benfluorex.

In 1997, a study was published that linked the appetite suppressants fenfluramine and dexfenfluramine to cardiac valve disease. At first, the risk was attributed to the two drugs when used in combination, but cases of valve disease were later reported in patients who had been treated exclusively with either fenfluramine or dexafenfluramine.3

In September 1997, the FDA asked manufacturers to voluntarily withdraw both treatments from the US market based on the results of echocardiograms of patients who had been on the medications.4 Findings supplied by physicians showed that approximately 30% of the evaluated patients had abnormal echocardiograms, despite having no symptoms. This rate was much higher than expected, forcing the FDA to take immediate action as well as to defend itself for not acting earlier. According to the FDA, before these physician reports there had been no information to suggest an association of heart valve disease with fenfluramine and dexfenfluramine. The FDA also pointed out that heart disease had also not been observed in a oneyear European study that had been used in the regulatory application for dexfenfluramine. Seeing the situation that the FDA was faced with, the EMA decided to take stronger measures by withdrawing the licences for fenfluramine and dexfenfluramine, as well as a number of other anti-obesity agents where clinical benefit was in doubt.3


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here